Strategic Expansion Sunstone Therapies is scaling in the psychedelic-assisted therapy space with a focus on clinical trial development and eventual clinical delivery, signaling opportunities to offer trial design partnerships, data capture systems, and infrastructure services to supporting clinics and partners.

Oncology-Driven Ops The cancer care model underpinning Sunstone’s operations and emphasis on multi-faceted, high-complexity care at scale suggests potential sales use-cases for integrated patient management platforms, logistics optimization, and training programs tailored for oncology-adjacent psychedelic therapies.

Public-Private Grants Recent funding from Reason for Hope and state-level IIT grants indicate readiness to collaborate on research initiatives; opportunities exist for grant-supported study platforms, data analytics, and compliant trial workflows.

Clinical Trial Expertise Sunstone has demonstrated leadership in psychedelic-assisted therapy delivery within medical settings and notable expansions of MDMA-assisted studies, presenting a path to offer research services, protocol consulting, and site management solutions.

Tech & Data Enablement A tech stack spanning Medidata, HealthCloud, and analytics tools points to opportunities for partnerships around EDC systems, data integration, patient engagement platforms, and quality-of-care analytics to support scalable therapy delivery.